.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Farmers Insurance
Chinese Patent Office
Novartis
Queensland Health
Express Scripts
Boehringer Ingelheim
Harvard Business School
Fish and Richardson
McKesson

Generated: June 25, 2017

DrugPatentWatch Database Preview

Indinavir sulfate - Generic Drug Details

« Back to Dashboard

What are the generic sources for indinavir sulfate and what is the scope of indinavir sulfate patent protection?

Indinavir sulfate
is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Indinavir sulfate has forty-one patent family members in thirty-five countries.

There are two drug master file entries for indinavir sulfate. Five suppliers are listed for this compound.

Summary for Generic Name: indinavir sulfate

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers / Packagers: see list5
Bulk Api Vendors: see list41
Clinical Trials: see list731
Patent Applications: see list3,540
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:indinavir sulfate at DailyMed

Pharmacology for Ingredient: indinavir sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-001Mar 13, 1996RXYesYes6,645,961► SubscribeY ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-006Apr 19, 2000DISCNNoNo6,689,761► Subscribe ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-005Dec 17, 1998DISCNNoNo6,645,961► SubscribeY ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-001Mar 13, 1996RXYesYes6,689,761► Subscribe ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-003Mar 13, 1996RXYesNo6,645,961► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: indinavir sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-001Mar 13, 19965,413,999► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-006Apr 19, 20005,413,999► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-005Dec 17, 19985,413,999► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-003Mar 13, 19965,413,999► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: indinavir sulfate

Country Document Number Estimated Expiration
Yugoslavia49417► Subscribe
CroatiaP960045► Subscribe
Poland182742► Subscribe
Hungary9800810► Subscribe
Australia4774896► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Chinese Patent Office
Teva
US Department of Justice
Fish and Richardson
Healthtrust
Citi
Covington
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot